18:58 , Sep 21, 2018 |  BC Week In Review  |  Company News

Corbus gets over 600 endocannabinoid-targeting compounds from Jenrin

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) acquired exclusive, worldwide rights to over 600 endocannabinoid system-targeting compounds from Jenrin Discovery LLC (Chadds Ford, Pa.) to treat inflammatory and fibrotic diseases. Jenrin will receive $250,000 upfront and is...